Frost & Sullivan
Lab Diary: Entry no.1
R&D software provider IDBS discusses the some of the top laboratory challenges experienced by scientists. Read more
Sciformix receives 2017 Global Pharmaceutical Scientific Process and Technology Outsourcing Customer Service Leadership award from Frost & Sullivan
Sciformix Corporation has announced that it has been awarded for best practices in Customer Service Leadership in the pharmaceutical scientific process outsourcing industry by market research company Frost & Sullivan Read more
Regenerative medicine bringing pharma and medtech closer together
Regenerative medicine is redefining medical technology synergies by combining stem cell technology with tissue engineering. Read more
Iran's insulin production and how it affects pharma
Y. Shashidhar, partner & managing director, South Asia, Middle East & North Africa, Frost & Sullivan talks about how the local production of insulin from Novo Nordisk’s new plant in Iran could impact the pharma market Read more
Webinar: Why Stem Cell Therapy?
Frost & Sullivan is to host a webinar on stem cell therapy pipeline and treatments innovating regenerative medicine Read more
Small animal imaging crucial for drug development
The use of small animal models in basic and preclinical research is now an integral part of developing and testing new pharmaceutical drugs prior to commercialisation. Read more
Small firms driving antibacterial drugs development
MDR-GNB (Multi-drug resistant gram-negative organisms) continue to pose a threat. New analysis finds that small firms are taking on the baton from big pharma in antibacterial drugs development. Read more
Cerner’s acquisition of Siemens: formation of an end-to-end healthcare IT solutions provider
Frost & Sullivan Healthcare IT research analyst Shruthi Parakkal comments on the future implications of this acquisition. Read more
Can regenerative medicine be the cure for cancer and other deadly diseases?
Frost & Sullivan's Global Regenerative Medicine Market finds approval rates and clinical activity buzz point to regenerative medicine being attractive for investors. Read more
Companion diagnostics benefit from fewer regulatory barriers in Europe
Future revisions to in-vitro diagnostics laws will offset the launch of new tests, in a market expected to soar to $1,295.1 million in 2018. Read more
